SCHEMBL30659432

SCHEMBL30659432

CC(C)(C)OC(=O)N1CCC(c2ccc3c(c2F)CCN3)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
THRB P10828 1/20 0.46
GPR119 Q8TDV5 7/20 0.45
ALOX5AP P20292 1/20 0.43
FEN1 P39748 1/20 0.43
MAPK1 P28482 2/20 0.43
HTT P42858 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41
DDB1 Q16531 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30659433 1.00 MAPT (0.46) MAPTKDM4ETHRBGPR119ALOX5AP
SCHEMBL31442861 1.00 MAPT (0.46) MAPTKDM4ETHRBGPR119ALOX5AP
SCHEMBL26100307 0.87 MAPK1 (0.50) MAPTKDM4ETHRBGPR119MAPK1
SCHEMBL30659439 0.85 THRB (0.46) MAPTKDM4ETHRBGPR119MAPK1
SCHEMBL30659271 0.82 THRB (0.47) MAPTKDM4ETHRBGPR119MAPK1
SCHEMBL30659256 0.80 MAPK1 (0.48) MAPTKDM4ETHRBGPR119MAPK1
SCHEMBL30659344 0.79 KDM4E (0.49) MAPTKDM4ETHRBGPR119MAPK1
SCHEMBL20438981 0.79 GPR119 (0.51) MAPTKDM4ETHRBGPR119ALOX5AP
SCHEMBL30844002 0.77 SMN1; SMN2 (0.51) MAPTKDM4ETHRBGPR119MAPK1
SCHEMBL31342284 0.77 STS (0.51) MAPTKDM4ETHRBGPR119ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-18 US disclosed
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-12-04 US disclosed
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders C4 THERAPEUTICS, INC. (US) 2025-09-23 US disclosed
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2025-04-17 US disclosed
EP-4536656-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 Therapeutics, Inc. (US) 2025-04-16 EP disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368631-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 MAPT 1299/4885KDM4E 465/4885THRB 4133/4885
US-20250122179-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 MAPT 1299/4885KDM4E 465/4885THRB 4133/4885
US-20250382285-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS CRBN, STUB1, CUL1 MAPT 1299/4885KDM4E 465/4885THRB 4133/4885
US-12421220-B2 Bicyclic-substituted glutarimide cereblon binders CRBN, STUB1, CUL1 MAPT 1299/4885KDM4E 465/4885THRB 4133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.